GSK Enters Race For OTC COVID-19 Test With Mammoth Biosciences As Partner
GSK partners with biotech firm Mammoth Biosciences to develop a home-use OTC nasal swab test for COVID-19 that works in less than 20 minutes. Mammoth says the firms will seek an FDA emergency use authorization for the test, roll it out first to clinics and will seek approval for OTC sales.
You may also be interested in...
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.
Sanofi benefits from coronavirus-triggered stockpiling in Q1, with Consumer Healthcare head Alan Main suggesting the pandemic may have turned more consumers into regular dietary supplement users
OTC access to any test to diagnose COVID-19 without supervision by a health care professional isn't on the near-term horizon for potential launches in the US. In addition to diagnostic kits, digital apps available to directly to consumers for COVID-19 testing on their own would face a steep climb to approval.